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Abstract: Pancreatic islet transplantation has become a recognized therapy for insulin-dependent
diabetes mellitus. During isolation from pancreatic tissue, the islet microenvironment is disrupted.
The extracellular matrix (ECM) within this space not only provides structural support, but also
actively signals to regulate islet survival and function. In addition, the ECM is responsible for growth
factor presentation and sequestration. By designing biomaterials that recapture elements of the native
islet environment, losses in islet function and number can potentially be reduced. Cell microarrays
are a high throughput screening tool able to recreate a multitude of cellular niches on a single chip.
Here, we present a screening methodology for identifying components that might promote islet
survival. Automated fluorescence microscopy is used to rapidly identify islet derived cell interaction
with ECM proteins and immobilized growth factors printed on arrays. MIN6 mouse insulinoma cells,
mouse islets and, finally, human islets are progressively screened. We demonstrate the capability of
the platform to identify ECM and growth factor protein candidates that support islet viability and
function and reveal synergies in cell response.
Keywords: ECM proteins; microarrays; pancreatic islets; high throughput screening
1. Introduction
Diabetes is a serious metabolic disorder, caused by inadequate insulin secretion from pancreatic
islets, and affects over 400 million people worldwide [1]. In Type 1 diabetes, autoimmune attack targets
the destruction of islets and their insulin-secreting β cells [2]. In type 2 diabetes, insulin resistance of
peripheral tissues can lead to chronically high blood sugar levels, placing an inordinate demand on
β cells for insulin supply, eventually overwhelming the capacity of β cells to respond [3]. The high
demand on β cells results in a high rate of malfunction and attrition within this cell population.
Over time, high glucose levels lead to secondary damage due to chronic hyperglycemia, especially
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of microvascular circulation, affecting the heart, retina and kidneys [4]. Since diabetes mellitus can
be regarded as a deficiency of a single cell type, it represents an attractive target for cell therapy.
β cell replacement therapy is already in clinical use in the form of cadaveric islet transplantation [5–7].
However, the supply of islets is insufficient to meet demand, limiting this treatment to a subset of
severely affected patients [8]. In addition, long-term islet graft survival rates are low [9]. Increasing islet
survival prior to and during the peri-transplant period is critical to transplant success [10].
Cellular function is informed by the cell microenvironment, which incorporates a mixture
of proteins and polysaccharides known as the extracellular matrix (ECM) in native tissue [11].
Although the composition and architecture of ECM varies broadly among tissues, the most basic
roles of ECM are to provide physical support and sites for cellular attachment [12–14]. The ECM
also is responsible for transmitting a multitude of chemical and mechanical signals to the cells that
regulate not only cell adhesion but also other key features of cellular physiology such as proliferation,
differentiation and migration [15]. The influence of ECM proteins within the islet basement and
interstitial membranes on pancreas development, function and pathogenesis is increasingly being
recognized [16–19]. Cell microarrays allow a large number of candidate materials to be screened
in parallel [20–24]. Biomolecules of interest are printed as microscale spots onto a glass or silicon
substrate, while the rest of supportive substrate is coated to resist non-specific cell, making every
printed spot an independent experimental replicate [21,25]. This study investigates the contribution
of ECM proteins and growth factors towards β cell attachment and insulin expression as a marker
of β cell function. We present a cell microarray platform to examine β cell and islet interactions with
various protein candidates for encapsulation matrices in a high throughput manner. A microarrayed
library with 201 different protein combinations was printed and used to examine attachment and
insulin expression of insulinoma cells as well as mouse and human islets. Several proteins supportive
of islet attachment to a substrate were identified.
2. Materials and Methods
2.1. Protein Microarray Fabrication
Plasma polymerization was performed to deposit a thin polymer coating on glass slides [26].
Briefly, glass slides were placed into the chamber of a custom-built plasma reactor. The plasma chamber
was pumped down to its base pressure of approximately 30 mTorr. Afterwards, the inlet valve was
gradually opened to allow air to flow into the chamber and to stabilize the pressure at 200 mTorr.
Subsequently, an air plasma with a RF frequency of 13.56 MHz, at a vapor pressure of 200 mTorr,
input power of 50 W and treatment time of 1 min was used to clean the surface of the slides in order to
ensure proper bonding of the subsequent plasma polymer layers to the glass substrate, followed by the
evacuation of the plasma chamber back down to its base pressure of 30 mTorr. Hexamethyldisiloxane
(HMDSO) (Sigma–Aldrich, St. Louis, MO, USA) vapors were introduced into the plasma chamber and
the pressure was observed to be stable at 200 mTorr for at least 1 min. This was followed by plasma
polymerization with a RF frequency of 13.56 MHz, at a vapor pressure of 200 mTorr, input power of
25 W and deposition time of 1 min. The chamber was pumped down to its base pressure and the
input monomer changed to allyl glycidyl ether (AGE) (Sigma–Aldrich). Plasma polymerization was
performed using AGE as the monomer at a pressure of 200 mTorr at 25 W input power for 1 min in
constant wave mode, then 2 min in pulsed mode (20 ms off, 1 ms on).
To provide islets with surrogate materials that furnish the same chemical signals that preserve
cell function in native tissue, ECM and growth factors were printed on the cell microarrays [27].
These included type I collagen (Col I) (Millipore, Bedford, MA, USA), type II collagen (Col II)
(Sigma–Aldrich), type III collagen (Col III) (Sigma–Aldrich), type IV collagen (Col IV) (Sigma–Aldrich),
laminin 111 (Ln) (Sigma–Aldrich), fibronectin (Fn) (Sigma–Aldrich), fibroblast growth factor 2 (FGF-2)
(Peprotech, Rocky Hill, NJ, USA), Insulin-like growth factor 2 (IGF-2) (R & D Systems, Minneapolis,
MN, USA), vascular endothelial growth factor (VEGF) (Sigma–Aldrich), exenatide (Exen) (Amylin
Pharmaceuticals, San Diego, CA, USA) and vitronectin (Vn) (Stem Cell Technologies, Vancouver, BC,
Canada). Briefly, all proteins used for printing were dissolved in Dulbecco’s modified phosphate
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buffered saline (dPBS, Sigma–Aldrich). The protein solutions were placed into a 384-well plate.
A high-precision robotic non-contact sciFLEXARRAYER S3 (Scienion, Berlin, Germany) was used
to spot 10 nL volume of proteins onto epoxy plasma polymer glass slides, yielding spots about
400–450 µm in diameter, with a center-to-center spacing of 1000 µm. After printing, arrays were
incubated in a humidified atmosphere for 16 h at 4 ˝C. To block nonspecific protein adsorption and cell
attachment, the printed slides were then incubated in 5% bovine serum albumin (BSA) (Sigma–Aldrich)
in sterile dPBS at pH 7 for 16 h at 37 ˝C. The arrayed slides were rinsed with sterile dPBS and 4 %
antibiotic-antimicotic solution (Sigma–Aldrich) before use.
2.2. Insulinoma Cell Culture
MIN6 clone B1 mouse insulinoma cells (ATCC CRL-11506) were grown in high-glucose Dulbecco’s
modified Eagle’s media (DMEM) (Sigma–Aldrich) with 2.5 mM GlutaMax (Life Technologies, Carlsbad,
CA, USA) containing 15% fetal bovine serum (FBS) (Sigma–Aldrich), 100 U/mL streptomycin,
100 µg/mL penicillin (Sigma–Aldrich) and 71 µM β-mercaptoethanol (Sigma–Aldrich) freshly added.
Cell cultures were maintained at 37 ˝C in 5% CO2 humidified air. The culture medium was changed
twice a week and cells were replated when reaching 80%–90% confluence. MIN6 cells (1ˆ 105 cells/mL)
were seeded onto cell microarray substrates and cultured in contact with arrays at 37 ˝C and 5% CO2.
Loosely attached cells were removed after 2 h by washing with prewarmed DMEM. The cells were
subsequently maintained in fresh high-glucose DMEM with 2.5 mM GlutaMax containing 15% FBS,
100 U/mL streptomycin, 100 µg/mL penicillin and 71 µM β-mercaptoethanol at 37 ˝C in a 5% CO2
humidified atmosphere for up to 2 days.
2.3. Primary Human Islet Culture
Human islets of Langerhans (female donor, 65 years old, with body mass index (BMI)
27.5) unsuitable for clinical islet transplantation were provided by the St. Vincent’s Institute
of Medical Research, Victoria, Australia under the auspices of the Australian Islet Consortium.
Approval for research use of human islets was obtained from the Royal Adelaide Hospital
(project 100205b, approved 29 September 2010) and University of South Australia (project 33541,
approved 14 August 2014) research ethics committees. Human islets cultured in CMRL 1066 medium
(Life Technologies) supplemented with 15% FBS (Life Technologies), 2 mM GlutaMax, 10 mM
4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid (HEPES) (Sigma–Aldrich). Primary human islets
(2 ˆ 103 islets/mL) were seeded onto the microarray and cultured in contact with arrays at 37 ˝C and
5% CO2. Non-bound islets were removed after 16 h by washing with prewarmed CMRL 1066 medium.
The cells were subsequently maintained in fresh CMRL 1066 medium including 15% FBS at 37 ˝C in a
5% CO2 humidified atmosphere for up to 2 days.
2.4. Primary Mouse Islet Isolation and Culture
All experimental procedures were approved by the Animal Ethics Committee of the University of
Adelaide and conform to the guidelines set out by the Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes. Primary pancreatic islets were isolated from 6- to 12-week-old
male C57B6 mice (University of Adelaide Laboratory Animal Services, Adelaide, SA, Australia).
Briefly, 3 mL cold M199 medium (Sigma–Aldrich) containing 0.67 mg collagenase (Liberase TL
grade; Roche Diagnostics, GmbH, Germany) per pancreas was infused into the pancreatic duct
in situ. The pancreas was removed and digested at 37 ˝C for 14–16 min. Islets were purified on a
Ficoll gradient (GE Healthcare, Amersham, UK). Following extensive washing, islets were grown
(37 ˝C, 5% CO2) in RPMI 1640 medium ( Sigma–Aldrich) supplemented with 2.5 mM GlutaMax,
100 U/mL streptomycin, 100 µg/mL penicillin, and 10% fetal calf serum for up to 2 days.
Primary mouse islets (2 ˆ 102 islets/mL) were seeded onto array and cultured in contact with arrays
at 37 ˝C and 5% CO2. Non-bound islets were rinsed off after 16 h by washing with prewarmed RPMI.
The cells were subsequently incubated in fresh CMRL 1066 medium including 15% FBS at 37 ˝C and
5% CO2 for 2 days.
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2.5. Fluorescence Microscopy and Cell Viability
For fluorescence microscopy, fixed cells were permeabilized with 0.3% Triton X-100
(Sigma-Aldrich) for 5 min at room temperature. Nuclei of cells were stained with 2 µg/mL
Hoechst 33342 (Life Technologies) for 10 min at room temperature. Actin was stained with 100 mM
Tetramethylrhodamine (TRITC)-labelled phalloidin (Sigma-Aldrich) for 45 min. Stained cells were
imaged using the Operetta High Content Imaging System (PerkinElmer, Hamburg, Germany),
which combines fluorescence microscopy with automated image acquisition and quantitative analysis.
Images were acquired using a 20ˆ long working distance (LWD) objective in wide-field mode in
combination with appropriate filters. The insulin intensity score was calculated by the Operetta
imaging system as the average pixel intensity within the microspot above a threshold fluorescence
value normalized to the number of cells within the spot.
A Live/Dead cell assay was also performed by incubating cells with final concentrations of
15 µg/mL fluorescein diacetate ( Sigma-Aldrich) and 5 mM propidium iodide (Sigma-Aldrich) for
3 min at 37 ˝C. Cells numbers stained with each dye were enumerated by the Operetta imaging system.
2.6. Immunocytochemistry
To stain insulin expressing cells, the microarray slides were washed with dPBS, fixed with 4%
paraformaldehyde solution for 20 min, permeabilized with 0.3% Triton X-100 in dPBS for 20 min,
and then blocked with 3% goat serum in dPBS for 30 min. Primary antibody (guinea pig anti-insulin,
EMD Millipore, Billerica, MA, USA) diluted in dPBS was incubated with the cells for 16 h at 4 ˝C.
The slides were washed with dPBS, followed by incubation with a goat anti-guinea pig rhodamine
conjugated antibody (Jackson ImmunoResearch, West Grove, PA, USA) diluted in dPBS incubated for
2 h at room temperature. The slides were then washed with dPBS and MilliQ water to remove the
salts, and air dried. The slides were imaged and quantified with the Operetta High Content Imaging
System. For quantitative analysis, images of insulin immunofluorescence were analyzed for the total
brightness of cytoplasmic insulin. Images were first corrected by subtracting the average background
fluorescence as determined from a non-cellular region in the images.
3. Results
3.1. Protein Microarray Fabrication
For the reproducible generation of the ECM protein and growth factor microarrays, glass
slides presenting epoxy functional groups for protein binding were created, in this case by coating
the slides with AGE plasma polymer [27]. In this study, 11 proteins were used to create a library of
201 microspots in a combinatorial manner (Table 1). A piezoelectric arrayer was used to dispense
consistent nanoliter volumes of protein solution. The layout of the microarray slide is shown in Figure 1.
The candidates investigated included ECM components, Ln, Fn and Vn, the collagen isoforms Col I,
Col II, Col III and Col IV, three growth factors, IGF2, FGF2, and VEGF, and the GLP-1 agonist Exen.
Col I, Col II, Col III, Col IV, Ln and Fn were printed as single proteins or binary combinations at a
concentration of 100 µg/mL, FGF-2, IGF-2, VEGF and Exen at a concentration of 25 µg/mL and Vn at
50 µg/mL. Combinations of three proteins were printed with one protein as the dominant component
(listed first), printed at the same concentration as listed above for single and binary component spots;
minor components (listed second and third) were printed at 2/3 concentration. Three array clusters,
each consisting of 201 combinatorial spots, were printed. Microspots measured 400–450 µm in diameter
and were spotted with a 1000 µm center-to-center distance (Figure 1). Each microarray consisted of
combination of 11 different ECM proteins and growth factors. The remaining unreacted epoxy groups
on the slide were then blocked with BSA to avoid non-specific cell or islet attachment in between the
spots (Figure 1).
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Table 1. Combinatorial protein microarrays layout used for array synthesis. The following 11 proteins were used: Type I collagen (Col I), type II collagen (Col II), type III
collagen (Col III), type IV collagen (Col IV), laminin (Ln), fibronectin (Fn), fibroblast growth factor 2 (FGF-2), insulin-like growth factor 2 (IGF-2), vascular endothelial
growth factor (VEGF), exenatide (Exen) and vitronectin (Vn). For single proteins and binary combinations, Col I, Col II, Col III, Col IV, Ln and Fn were printed at a
concentration of 100 µg/mL; FGF-2, IGF-2, VEGF and Exen at a concentration of 25 µg/mL; and Vn at 50 µg/mL. In ternary combinations, the first protein listed
was printed as the major component, at the concentration listed above, the second and third listed components were printed at 2/3 the concentration of the first
listed protein.
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growth factors. The remaining unreacted epoxy groups on the slide were then blocked with BSA to 
avoid non-specific cell or islet attachment in between the spots (Figure 1). 
 
Figure 1. Schematic of the protein microarray on the glass slide with three blocks of 201 protein 
including the dimensions of the blocks and their separation. The left inset shows spot dimensions 
and spacing. The AGEpp coating displays epoxy groups, enabling covalent conjugation of proteins 
to the surface (middle inset). The non-printed surface was passivated with bovine serum albumin 
(BSA) (right inset). 
 
Figure 1. Schematic of the protein i r rr t e gla s slide with thr e blocks of 201 protein
including the dimensions of the blocks and their separ tion. The l ft inset shows spot dimensions and
sp cing. The AGEpp coating displays epoxy groups, enabli g covalent co jugation of proteins to the
surface (middl inset). The non-pri ted surface was passivated with bovine serum albumin (BSA)
(right inset).
3.2. Profiling Cell Adhesion to Different Protein Combinations
The cell microarrays were first used to compare the adhesion of MIN6 mouse insulinoma cells to
a panel of ECM proteins and growth factors. Adhesion was measured on triplicate arrays (Figure 2
and Figure S1). Triple protein combinations dominated the top 10% of candidates identified (Table 2).
FGF2 was present as the major component in seven of these twenty combinations. Vn and Fn occurred
most frequently (9/20 and 8/20) as minor components of these top ranked combinations. While there
was no significant difference in the number of cells populating each spot on the top 10% of candidates
(p > 0.05, ANOVA), the number of cells present on the microspots in this 10% of candidates was
eight-fold higher than the bottom 10% (p < 0.001, t-test with Welch’s correction).
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(a) map of cell attachment MIN6 cells for all of 201 protein combinations in the microarray; and (b) 
representative images of MIN6 cells adhering to protein spots (E11, Ln/Fn/Exen, D14, FGF-2/Col 
IV/Vn, D5, FGF-2/Vn) demonstrating selective adhesion in the locations of protein, N = 3. 
Table 2. Lead candidate combinations for MIN6 adhesion and growth, identified using the protein 
microarray. 
Well ID Formulation Cells Attached Per Spot 
D14 FGF-2/Col IV/Vn 168 ± 11.7 
D11 Ln/Fn/VEGF 154 ± 6.39 
N7 Col IV/Fn/IGF-2 153 ± 12.4 
D12 FGF-2/Col I/Col III 152 ± 10.0 
L7 Col IV/Ln/Vn 152 ± 10.5 
L13 FGF-2/Col III/Vn 151 ± 9.82 
F11 Ln/Fn/Vn 151 ± 11.0 
L4 Fn/VEGF 145 ± 21.5 
N4 Fn/Vn 138 ± 11.3 
K4 Fn/IGF-2 131 ± 16.6 
M11 Ln/IGF-2/Vn 126 ± 7.63 
E14 FGF-2/Ln/Fn 125 ± 22.1 
F5 IGF-2/Exen 125 ± 23.7 
B5 FGF-2/VEGF 122 ± 19.1 
J4 Fn/FGF-2 120 ± 9.91 
N13 FGF-2/Col IV/Fn 117 ± 7.94 
K1 Vn 115 ± 7.94 
M2 Col II/IGF-2 113 ± 11.3 
Figure 2. Quantificati f MIN6 adhesion to the spots on protein microarray (for l yout see
Table 1): (a) map of cell attachment MIN6 cells for all of 201 protein combinations in the microarray;
and (b) representative images of MIN6 cells adhering to protein spots (E11, Ln/Fn/Exen, D14,
FGF-2/Col IV/Vn, D5, FGF-2/Vn) demonstrating selective adhesion in the locations of protein, N = 3.
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Table 2. Lead candidate combinations for MIN6 adhesion and growth, identified using the
protein microarray.
Well ID Formulation Cells Attached Per Spot
D14 FGF-2/Col IV/Vn 168 ˘ 11.7
D11 Ln/Fn/VEGF 154 ˘ 6.39
N7 Col IV/Fn/IGF-2 153 ˘ 12.4
D12 FGF-2/Col I/Col III 152 ˘ 10.0
L7 Col IV/Ln/Vn 152 ˘ 10.5
L13 FGF-2/Col III/Vn 151 ˘ 9.82
F11 Ln/Fn/Vn 151 ˘ 11.0
L4 Fn/VEGF 145 ˘ 21.5
N4 Fn/Vn 138 ˘ 11.3
K4 Fn/IGF-2 131 ˘ 16.6
M11 Ln/IGF-2/Vn 126 ˘ 7.63
E14 FGF-2/Ln/Fn 125 ˘ 22.1
F5 IGF-2/Exen 125 ˘ 23.7
B5 FGF-2/VEGF 122 ˘ 19.1
J4 Fn/FGF-2 120 ˘ 9.91
N13 FGF-2/Col IV/Fn 117 ˘ 7.94
K1 Vn 115 ˘ 7.94
M2 Col II/IGF-2 113 ˘ 11.3
E13 FGF-2/Col II/Vn 113 ˘ 22.9
C13 FGF-2/Col II/VEGF 112 ˘ 11.72
We then attempted to use this platform to identify protein combinations that are conducive
to islet attachment. Mouse islet attachment to the library of substrates embodied in the array
was probed. The islet populations were anticipated to adhere with different avidities to various
combinations of ECM protein and growth factor due to their specific cell surface receptor expression,
and additional three-dimensional properties of mouse and human islets. We quantified adhesion
patterns by the number of nuclei visible in the focal plane. Primary mouse islet attachment was
highest on spots comprised of Col IV/Col II/Fn (H6), Col IV/Col II/IGF-2 (J6), Col IV/Col II/Vn (M6),
Ln/Col I/Exen (G9), FGF-2/Col I/Fn (G12) and Col IV/Col II/VEGF (K6) (Figures S2a,b and S3).
These combinations achieved an average adhesion measure of >100 nuclei per spot. The combinations
identified as optimal for mouse islet adhesion were distinct from those obtained for MIN6 cells,
clustering in the second and third quartiles of the MIN6 dataset. In contrast to conclusions drawn
from the MIN6 data, Col IV was the most prevalent protein in the highly ranked candidates.
To demonstrate proof-of-concept using human islets, adhesion of a donor islet preparation was
assessed using the same array format. The best primary human islet attachment (>100 cells per spot)
was observed on combinations of Col IV/Col II/Ln (G6), Col IV/Col II/Fn (H6), Col IV/Col I/Vn
(E6), Ln/Col II/Vn (B10), FGF-2/Col I/Exen (J12) and FGF-2/Fn/Vn (M14) (Figures S2c,d and S4).
Similar to mouse islets, Col IV recurred as the major component in these highest ranked combinations.
3.3. Cell Viability and Insulin Synthesis by MIN6 Cells
To assess basic β cell function in more detail, MIN6 cells were tested on the protein microarray to
investigate cell viability. MIN6 cells showed viability of greater than 95% on all spots, as determined
by propidium iodide/fluorescein diacetate staining (Figure 3a and Figure S5). To compare insulin
production of MIN6 cells on the microarray spots, the cells were cultured for an additional 48 h,
stained with anti-insulin antibodies and visualized by fluorescence microscopy (Figures 3b and 4).
Figure 4 shows that the majority of MIN6 cells on the microarray stained strongly with the anti-insulin
antibody. No direct correlation was found between insulin expression and cell viability or cell number
(R2 = 0.034 and 0.0073, linear regression model, Figure S6). Fourteen combinations were identified
as exhibiting particularly high insulin expression (Figure 3c). These combinations produced average
insulin staining intensities that were significantly greater than the rest of the candidates tested (p = 0.001,
ANOVA/Tukey post hoc test). Notably, Ln was the dominant factor in eleven of the fourteen high
Microarrays 2016, 5, 21 9 of 13
expressing combinations. Thirteen combinations contained at least one collagen component and
nine contained a growth factor (IGF2, FGF2 or VEGF). FGF2 featured in six of these combinations.
Exen, known to activate the GLP-1 receptor, leading to an increase in insulin synthesis and release
from β cells [28], was present in two of the top three candidate combinations identified. However,
Fn was absent from all combinations in the high expressing set.
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of the mean (SEM). n = 3
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and survival. One important aspect in this line of research is to investigate interactions betwee
isl ts and immobilized ECM protein and growth fact rs to find ways to maintain and improve
islet viability and functio duri g the peri-transplant period. The influence of ECM proteins on
islet viability and function is well know , and some f these proteins have been incorporated into
scaffold and encapsulation materials for islet transpl nt [12,19,28,29]. However, previous studies
have been limited in the numbers of combinations of proteins and functional peptides able to be
tested. To address this issue, the microarray format described here was designed to screen ECM
proteins and growth factors i a combinatorial ma ner, providing crucial i formation about islet
attach ent, via ility and insulin secretion. Furthermore, the array was designed to allow screening of
high numbers of immobilized proteins with minimal c st an time. The quantitative evalu tions of
cell attachment require repr ducible substrate preparation cell culture procedures. The e oxy plasma
polymer-coate surface in combination with microprinting was utilized to create protein microarrays.
This allowed the covalent attachment of protein combinations in t e form of printed microsp ts on the
surface. Epoxy groups in betwee the spots were reacted with BSA t block cell attachment t ere.
Here we showed that microarrays are capable of differentiating β cell adhesion patterns and
functional response across a library of candidate su strates [12,19,29,30]. Insulin expression correlated
with Ln and collagen content. Increased insulin gene expression on both lami in and collagen
substrates has bee reported previously [28–30]. Intriguingly, while Col I, Col III and Col IV have
been detected within the islet basement membrane of several species [12], Col II has not, to our
knowledge, been associated with islet ECM or islet function previously. This effect may be due to
integrin binding sites common between the isoforms of collagen, allowing them to substitute for one
a other [31]. In contrast to previous work showing an increase i insulin gene expression and release
on Fn-containing substrates [29,30], Fn was notably absent from the top ca didates identified for
insulin expression. The addition of growth factors to ECM protein substrates appeared to further
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benefit MIN6 and islet adhesion and increased insulin expression. FGF2, known to be involved
in pancreatic development [32,33], was identified as a frontrunner for further investigation. While
MIN6 viability appeared insensitive to substrate composition, the limited time period of culture may
have been insufficient to elucidate differences in long term viability. Col IV combinations ranked
highly for both mouse and human islet attachment. These proteins are abundant in the islet basement
membrane of both species, which is damaged during islet isolation [34,35]. We note that islet adhesion
is more challenging to study using the array format, due to the weaker adhesion of aggregates to
the substrate than single cells. In its current permutation, the microarray platform is also limited to
be the study of biomolecules and markers localized to the cell population present at each microspot.
However, segregation of test candidates in individual culture environments would allow secreted
proteins, such as insulin, to be probed [36].
The utility of the ECM microarray platform extends beyond the specific application of islet
attachment. Although this study documents the ability to profile adhesion patterns, cells bound to
the arrays can be kept in culture for multiple days to monitor long-term responses to ECM such as
cell death, proliferation and alterations in gene or protein expression. Overall, the ECM microarrays
will enhance our ability to study a host of questions as they pertain to both basic biological and
clinical settings.
5. Conclusions
We have developed a cell microarray platform and an assay protocol for accurate and sensitive
analysis of differential MIN6 cell and islet population attachment to biomaterial surfaces in a high
throughput manner while using minimum amounts of adhesive substrate and cells. We demonstrated
the power of this approach in defining the substrate requirements that support adhesion of islets and
islet derived cells, and then investigated the influence of these substrates on viability and insulin
expression using MIN6 cells as a model for the β cell population within islets. We anticipate that
the findings from the microarray study will enable the engineering of protein coatings on scaffold
materials for β cell or islet transplantation.
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